非那雄胺联合二甲双胍治疗老年人良性前列腺增生并糖尿病临床疗效分析
비나웅알연합이갑쌍고치료노년인량성전렬선증생병당뇨병림상료효분석
Clinical effect of combined finasteride and metformin treatment for benign prostatic hyperplasia plus diabetes mellitus
  • 万方数据
    中华老年医学杂志 중화노년의학잡지
    Chinese Journal of Geriatrics
    2012年 11期 932-934 ,共3页

    余小祥%何世安%程时武%周大庆%莫曾南%王强%张瑞明%李文刚%江波%刘尚文%王坚%禹长杰%何猛%庞翔

    여소상%하세안%정시무%주대경%막증남%왕강%장서명%리문강%강파%류상문%왕견%우장걸%하맹%방상

    前列腺增生%糖尿病,2型%非那特利%二甲双胍 前列腺增生%糖尿病,2型%非那特利%二甲雙胍
    전렬선증생%당뇨병,2형%비나특리%이갑쌍고
    Prostatic hyperplasia%Diabetes mellitus,type 2%Finasteride%Metformin
    目的 探讨长期应用非那雄胺联合盐酸二甲双胍治疗良性前列腺增生合并2型糖尿病的临床疗效及安全性. 方法 对106例良性前列腺增生合并2型糖尿病患者给予非那雄胺和盐酸二甲双胍治疗12个月以上,检测并比较治疗前后前列腺体积(PV)、前列腺特异性抗原(PSA)、国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(Qmax)、残余尿量(RU)、体质指数(BMI),三酰甘油(TG)等指标,同时观察其不良反应. 结果 患者治疗前后PV分别为(56.40±18.75)ml和(42.40±19.68)ml,PSA分别为(3.65±1.08)μg/L和(1.76±0.66)μg/L,IPSS分别为(22.58±9.45)分和(16.67±7.56)分,QOL分别为(4.22±0.87)分和(2.36±0.74)分,Qmax分别为(8.32±2.42)ml/s和(15.48±3.61)ml/s,RU分别为(68.36±19.25) ml和(36.42±13.91)ml,BMI分别为(28.52±3.73)kg/m2和(19.76±1.88) kg/m2,TG分别为(2.52±0.43) mmol/L和(1.38±0.52)mmol/L;治疗前后上述指标比较,差异均有统计学意义(P＜0.05). 结论 长期应用非那雄胺联合盐酸二甲双胍治疗良性前列腺增生合并2型糖尿病安全有效,二者可能有协同作用.
    목적 탐토장기응용비나웅알연합염산이갑쌍고치료량성전렬선증생합병2형당뇨병적림상료효급안전성. 방법 대106례량성전렬선증생합병2형당뇨병환자급여비나웅알화염산이갑쌍고치료12개월이상,검측병비교치료전후전렬선체적(PV)、전렬선특이성항원(PSA)、국제전렬선증상평분(IPSS)、생활질량평분(QOL)、최대뇨류솔(Qmax)、잔여뇨량(RU)、체질지수(BMI),삼선감유(TG)등지표,동시관찰기불량반응. 결과 환자치료전후PV분별위(56.40±18.75)ml화(42.40±19.68)ml,PSA분별위(3.65±1.08)μg/L화(1.76±0.66)μg/L,IPSS분별위(22.58±9.45)분화(16.67±7.56)분,QOL분별위(4.22±0.87)분화(2.36±0.74)분,Qmax분별위(8.32±2.42)ml/s화(15.48±3.61)ml/s,RU분별위(68.36±19.25) ml화(36.42±13.91)ml,BMI분별위(28.52±3.73)kg/m2화(19.76±1.88) kg/m2,TG분별위(2.52±0.43) mmol/L화(1.38±0.52)mmol/L;치료전후상술지표비교,차이균유통계학의의(P＜0.05). 결론 장기응용비나웅알연합염산이갑쌍고치료량성전렬선증생합병2형당뇨병안전유효,이자가능유협동작용.
    Objective To evaluate the safety and efficiency of combined finasteride and metformin on benign prostatic hyperplasia (BPH) with type 2 diabetes mellitus(T2DM).Methods Totally 106 patients with BPH plus T2DM received finasteride and metformin treatment for over 12months.Before and after treatment,the side effects and following parameters were measured:prostatic volume (PV),prostate-specific antigen(PSA),international prostate symptom score (IPSS),quality of life (QOL),the maximum flow rate of urinary (Qmax),residual urine(RU),body mass index (BMI),cholesterol (TG).Results There were obvious changes in the following:PV decreased from (56.40±18.75)ml to(42.40± 19.68) ml,PSA decreased from(3.65± 1.08) μg/L to (1.76±0.66)μg/L,IPSS decreased from(22.58±9.45)to(16.67±7.56),QOL decreased from(4.22± ±0.87) to (2.36 ± 0.74),Qmax increased from(8.32±2.42)ml/s to(15.48±3.61)ml/s,RU decreased form(68.36±19.25)ml to(36.42±13.91)ml,BMI decreased from(28.52±3.73)kg/m2 to (19.76± 1.88)kg/m2,TG decreased from (2.52 ± 0.43) mmol/L to (1.38 ± 0.52) mmol/L.The changes of PV,PSA,IPSS,QOL,Qmax,RU,BMI and TG were statistically significant (all P＜0.05).Conclusions Long term combined finasteride and metformin treatment for BPH plus T2DM is effective and safe.And the two drugs may be improve the efficacy each other.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문